Download PDF
Horm Metab Res 2003; 35(11/12): 651-655
DOI: 10.1055/s-2004-814141
Original
© Georg Thieme Verlag Stuttgart · New York

Rapid Induction of IGF-IR Signaling in Normal and Tumor Tissue Following Intravenous Injection of IGF-I in Mice

A.  V.  Lee1, 2 , S.  T.  Taylor4 , J.  Greenall4 , J.  D.  Mills4 , D.  W.  Tonge4 , P.  Zhang1 , J.  George3 , M.  L.  Fiorotto3 , D.  L.  Hadsell2, 3
  • 1The Breast Center, Department of Medicine, Baylor College of Medicine, Houston, TX
  • 2Department of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX
  • 3USDA/ARS, Children’s Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX
  • 4AstraZeneca UK, Alderley Park, Macclesfield, Cheshire, UK
Further Information

Publication History

Received 21 August 2003

Accepted after Revision 18 November 2003

Publication Date:
07 January 2004 (online)

Also available at
    Permissions and Reprints

Abstract

The detection of IGF-IR signaling in animal models has important implications for determining the role of this receptor in normal physiology and tumor growth. While many reports have correlated changes in plasma IGF-I levels in vivo with biological responses, few have shown that altered IGF-I levels can directly affect signaling within normal or tumor tissue. Here, we present new data that shows how the intravenous (IV) injection of IGF-I can be used to directly examine IGF signaling at the tissue level. Tail-vein IV injection of IGF-I into mice resulted in a rapid and dose-dependent activation of the IGF-I receptor and downstream phosphorylation of Akt and ERK1/2 in liver, kidney, and mammary gland. Similarly, IV IGF-I rapidly stimulated signaling in HT-29 colorectal and in MCF-7 breast cancer xenografts. This study shows how IV IGF injection can be used to examine the signaling mechanisms used by IGF-IR, in both normal mammary tissue and during tumor growth, and may provide a model for the characterization of IGF inhibitors.

Key words

IGF-I - Mammary gland - Kidney - Liver - Xenografts - Signal transduction

References

  • 1 Baserga R, Morrione A. Differentiation and malignant transformation: two roads diverged in a wood.  J Cell Biochem. 1999;  Suppl 68-75
    CrossrefPubMedGoogle Scholar
  • 2 Dupont J, LeRoith D. Insulin and insulin-like growth factor I receptors: similarities and differences in signal transduction.  Horm Res. 2001;  55 Suppl 2 22-26
    CrossrefPubMedGoogle Scholar
  • 3 Surmacz E. Growth factor receptors as therapeutic targets: strategies to inhibit the insulin-like growth factor I receptor.  Oncogene. 2003;  22 6589-6597
    CrossrefPubMedGoogle Scholar
  • 4 Butler A A, Yakar S, LeRoith D. Insulin-like growth factor-I: compartmentalization within the somatotropic axis?.  News Physiol Sci. 2002;  17 82-85
    PubMedGoogle Scholar
  • 5 Wu Y, Yakar S, Zhao L, Hennighausen L, LeRoith D. Circulating insulin-like growth factor-I levels regulate colon cancer growth and metastasis.  Cancer Res. 2002;  62 1030-1035
    PubMedGoogle Scholar
  • 6 Yakar S, Liu J L, Fernandez A M, Wu Y, Schally A V, Frystyk J, Chernausek S D, Mejia W, LeRoith D. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity.  Diabetes. 2001;  50 1110-1118
    CrossrefPubMedGoogle Scholar
  • 7 Chang P Y, Goodyear L J, Benecke H, Markuns J S, Moller D E. Impaired insulin signaling in skeletal muscles from transgenic mice expressing kinase-deficient insulin receptors.  J Biol Chem. 1995;  270 12 593-12 600
    PubMedGoogle Scholar
  • 8 Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills G B, Lee A V. Insulin-Like Growth Factor-I Inhibits Progesterone Receptor Expression in Breast Cancer Cells via the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Pathway: Progesterone Receptor as a Potential Indicator of Growth Factor Activity in Breast Cancer.  Mol Endocrinol. 2003;  17 575-588
    CrossrefPubMedGoogle Scholar
  • 9 Lee A V, Zhang P, Ivanova M, Bonnette S, Oesterreich S, Rosen J M, Grimm S, Hovey R C, Vonderhaar B K, Kahn C R, Torres D, George J, Mohsin S, Allred D C, Hadsell D L. Developmental and hormonal signals dramatically alter the localization and abundance of insulin receptor substrate proteins in the mammary gland.  Endocrinol. 2003;  144 2683-2694
    CrossrefPubMedGoogle Scholar
  • 10 Kleinberg D L, Feldman M, Ruan W. IGF-I: an essential factor in terminal end bud formation and ductal morphogenesis.  J Mammary Gland Biol Neoplasia. 2000;  5 7-17
    CrossrefPubMedGoogle Scholar
  • 11 Lee A V, Hilsenbeck S G, Yee D. IGF system components as prognostic markers in breast cancer.  Breast Cancer Res Treat. 1998;  47 295-302
    CrossrefPubMedGoogle Scholar
  • 12 Dominici F P, Hauck S, Argentino D P, Bartke A, Turyn D. Increased insulin sensitivity and upregulation of insulin receptor, insulin receptor substrate (IRS)-1 and IRS-2 in liver of Ames dwarf mice.  J Endocrinol. 2002;  173 81-94
    CrossrefPubMedGoogle Scholar
  • 13 Li M, Li C, Parkhouse W S. Differential effects of des IGF-1 on Erks, AKT-1 and P70 S6K activation in mouse skeletal and cardiac muscle.  Mol Cell Biochem;. 2002;  236 115-122
    CrossrefPubMedGoogle Scholar
  • 14 Di Cola G, Cool M H, Accili D. Hypoglycemic effect of insulin-like growth factor-1 in mice lacking insulin receptors.  J Clin Invest. 1997;  99 2538-2544
    PubMedGoogle Scholar
  • 15 Saad M J, Araki E, Miralpeix M, Rothenberg P L, White M F, Kahn C R. Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistance.  J Clin Invest. 1992;  90 1839-1849
    PubMedGoogle Scholar
  • 16 Giddings S J, Carnaghi L R. Insulin receptor gene expression during development: developmental regulation of insulin receptor mRNA abundance in embryonic rat liver and yolk sac, developmental regulation of insulin receptor gene splicing, and comparison to abundance of insulin-like growth factor 1 receptor mRNA.  Mol Endocrinol. 1992;  6 1665-1672
    CrossrefPubMedGoogle Scholar
  • 17 Kjeldsen T, Andersen A S, Wiberg F C, Rasmussen J S, Schaffer L, Balschmidt P, Moller K B, Moller N P. The ligand specificities of the insulin receptor and the insulin-like growth factor I receptor reside in different regions of a common binding site.  Proc Natl Acad Sci USA. 1991;  88 4404-4408
    PubMedGoogle Scholar
  • 18 Rubini M, D’Ambrosio C, Carturan S, Yumet G, Catalano E, Shan S, Huang Z, Criscuolo M, Pifferi M, Baserga R. Characterization of an antibody that can detect an activated IGF-I receptor in human cancers.  Exp Cell Res. 1999;  251 22-32
    CrossrefPubMedGoogle Scholar
  • 19 Firth S M, Baxter R C. Cellular actions of the insulin-like growth factor binding proteins.  Endocr Rev. 2002;  23 824-854
    CrossrefPubMedGoogle Scholar
  • 20 Bar R S, Clemmons D R, Boes M, Busby W H, Booth B A, Dake B L, Sandra A. Transcapillary permeability and subendothelial distribution of endothelial and amniotic fluid insulin-like growth factor binding proteins in the rat heart.  Endocrinol. 1990;  127 1078-1086
    PubMedGoogle Scholar
  • 21 Walton P E, Gopinath R, Burleigh B D, Etherton T D. Administration of recombinant human insulin-like growth factor I to pigs: determination of circulating half-lives and chromatographic profiles.  Horm Res. 1989;  31 138-142
    PubMedGoogle Scholar
  • 22 Luetteke N C, Qiu T H, Fenton S E, Troyer K L, Riedel R F, Chang A, Lee D C. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development.  Development. 1999;  126 2739-2750
    PubMedGoogle Scholar

A. V. Lee, Ph. D.

Breast Center · Room N1110 · Baylor College of Medicine

One Baylor Plaza · MS:600 · Houston · TX 77030

Phone: + 1 (713) 798-1624

Fax: + 1 (713) 798-1642

Email: avlee@breastcenter.tmc.edu

      >